Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2013

01-04-2013 | Editorial

Ghrelin: a new treatment for non-alcoholic fatty liver disease?

Published in: Endocrine | Issue 2/2013

Login to get access

Excerpt

Li et al. [1] report in this issue of the journal that administration of ghrelin might improve inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development (NAFLD). …
Literature
1.
J.H. Yan Li, L. Lake, C. Xuehui, P.Hua, C. Meng, Z. Qinggui, Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine. (2012). doi:10.​1007/​s12020-012-9761-5
2.
S.E. Mahady, J. George, Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin. Liver Dis. 16, 631–645 (2012)PubMedCrossRef
3.
M. Heuer, G.M. Kaiser, A. Kahraman, M. Banysch, F.H. Saner, Z. Mathe, G. Gerken, A. Paul, A. Canbay, J.W. Treckmann, Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 86, 107–113 (2012)PubMedCrossRef
4.
T. Takamura, H. Misu, T. Ota, S. Kaneko, Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver [Review]. Endocr. J. (2012)
5.
N.J. de Wit, L.A. Afman, M. Mensink M. Muller, Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. (2012)
6.
P.J. Delhanty, S.J. Neggers, A.J. Van der Lely, Ghrelin: the differences between acyl- and des-acyl ghrelin. Eur. J. Endocrinol. (2012)
7.
M. Estep, M. Abawi, M. Jarrar, L. Wang, M. Stepanova, H. Elariny, A. Moazez, Z. Goodman, V. Chandhoke, A. Baranova, Z.M. Younossi, Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes. Surg. 21, 1750–1757 (2011)PubMedCrossRef
8.
Y. Okamatsu, K. Matsuda, I. Hiramoto, H. Tani, K. Kimura, Y. Yada, T. Kakuma, S. Higuchi, M. Kojima, T. Matsuishi, Ghrelin and leptin modulate immunity and liver function in overweight children. Pediatr. Int. 51, 9–13 (2009)PubMedCrossRef
9.
Y. Gutierrez-Grobe, I. Villalobos-Blasquez, K. Sanchez-Lara, A.R. Villa, G. Ponciano-Rodriguez, M.H. Ramos, N.C. Chavez-Tapia, M. Uribe, N. Mendez-Sanchez, High ghrelin and obestatin levels and low risk of developing fatty liver. Ann. Hepatol. 9, 52–57 (2010)PubMed
10.
S. Aydin, Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors? Ann. Hepatol. 11, 145–146 (2012)PubMed
11.
P.J. Delhanty, Y. Sun, J.A. Visser, A. van Kerkwijk, M. Huisman, W.F. van Ijcken, S. Swagemakers, R.G. Smith, A.P. Themmen, A.J. van der Lely, Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS ONE 5, e11749 (2010)PubMedCrossRef
Metadata
Title
Ghrelin: a new treatment for non-alcoholic fatty liver disease?
Publication date
01-04-2013
Published in
Endocrine / Issue 2/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9800-2

Other articles of this Issue 2/2013

Endocrine 2/2013 Go to the issue

Review

HbA1c for screening and diagnosis of diabetes mellitus

Letter to the Editor

Morphometric characteristics, cell proliferation parameters and apoptosis indices do not correlate with tendency to relapse in non-functioning pituitary macroadenomas

Original Article

The effects of sonographic and demographic features and needle size on obtaining adequate cytological material in sonography-guided fine-needle aspiration biopsy of thyroid nodules

Original Article

Hematological parameters are associated with metabolic syndrome in Japanese community-dwelling persons

Original Article

Levothyroxine replacement therapy with vitamin E supplementation prevents oxidative stress and cognitive deficit in experimental hypothyroidism

Original Article

Reference values for handgrip strength in young people of both sexes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits